Campbell & Co Investment Adviser’s Lexicon Pharmaceuticals LXRX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,900	Closed	-$47K	–	808
2021 Q4	$47K	Sell	11,900 -19,500	-62%	-$94.7K	0.02%	590
2021 Q3	$151K	Buy	+31,400	New	+$129K	0.05%	544
2021 Q2	–	Sell	-103,100	Closed	-$605K	–	634
2021 Q1	$605K	Buy	+103,100	New	+$714K	0.37%	72
2019 Q2	–	Sell	-21,370	Closed	-$119K	–	625
2019 Q1	$119K	Buy	+21,370	New	+$130K	0.06%	483

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell & Co Investment Adviser's LXRX Position: Q1 2022 in Review

Campbell & Co Investment Adviser sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2022, closing a stake of 11,900 shares — an estimated $47K sold.

Campbell & Co Investment Adviser first reported a position in LXRX in Q1 2019 and held it in 4 quarters. The position peaked at $605K in Q1 2021. 101 funds tracked by Wall St. Rank hold LXRX as of Q1 2022.

Campbell & Co Investment Adviser reported no remaining Lexicon Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Campbell & Co Investment Adviser sold 11,900 Lexicon Pharmaceuticals shares in Q1 2022, an estimated $47K.
Campbell & Co Investment Adviser first reported a position in Lexicon Pharmaceuticals in Q1 2019 and held it in 4 quarters.
Campbell & Co Investment Adviser's Lexicon Pharmaceuticals position peaked at $605K in Q1 2021.
101 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2022, filed 9 May 2022.